← Leaderboards
Mark Puder
Boston Children'S Hospital
$3,123,512
Attributed
$3,123,512
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $660.1K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
FDA$2,484,017 · 3
NIH$639,495 · 1
By mechanism
R01$2,484,017 · 3
K08$639,495 · 1
Top collaborators
No co-investigators on record.
Most similar at Boston Children'S Hospital
Same institution · by research overlap
- Clifford J Woolf$42,375,557
- Richard I. Gregory$15,975,785
- Judy Lieberman$53,446,005
- Morris F. White$23,937,236
- Richard Sang-Yong Lee$4,165,332
Others in their field
Top investigators on “Fatty Liver”
- Steven Kyle Grinspoon · Massachusetts General Hospital$28,908,746
- Jeffrey S Glenn · Stanford University$28,620,975
- Gerald I Shulman · Yale University$28,464,352
- James A Tonascia · Johns Hopkins University$28,454,878
- Arun J Sanyal · Virginia Commonwealth University$24,254,529
- Pamela Susan Douglas · Duke University$22,843,024
Research focus
Fatty LiverFatty Acid Glycerol EstersAdultFatty AcidsAdvisory CommitteesBaseBiochemistryAdvanced DevelopmentAnimalsExtracellular MatrixAwardCirrhosisComplementComplicationCytokineDietAnimal ModelDoseCarbohydratesEnzyme ActivityCareerEnzymesChildHepatic
Grant awards (13)
A 90 day, Phase 3, Open Labeled Exploratory Study of RELiZORB to Evaluate Safety, Tolerability, and Nutrient Absorption in Children with Short Bowel Syndrome who are Dependent on Parenteral Nutrition$365,285
R01 · FY2025 · FD · contact PI
A 90 day, Phase 3, Open Labeled Exploratory Study of RELiZORB to Evaluate Safety, Tolerability, and Nutrient Absorption in Children with Short Bowel Syndrome who are Dependent on Parenteral Nutrition$298,102
R01 · FY2023 · FD · contact PI
A 90 day, Phase 3, Open Labeled Exploratory Study of RELiZORB to Evaluate Safety, Tolerability, and Nutrient Absorption in Children with Short Bowel Syndrome who are Dependent on Parenteral Nutrition$660,139
R01 · FY2021 · FD · contact PI
Cholestasis Reversal (Phase ll): Efficacy of lV Fish Oil$286,971
R01 · FY2010 · FD · contact PI
Cholestasis Reversal (Phase ll): Efficacy of lV Fish Oil$263,803
R01 · FY2009 · FD · contact PI
Cholestasis Prevention: Efficacy of IV Fish Oil$144,932
R01 · FY2009 · FD · contact PI
Mechanisms of Hepatic Steatosis Prevention$127,683
K08 · FY2009 · DK · contact PI
Cholestasis Reversal (Phase ll): Efficacy of lV Fish Oil$250,757
R01 · FY2008 · FD · contact PI
Cholestasis Prevention: Efficacy of IV Fish Oil$214,028
R01 · FY2008 · FD · contact PI
Mechanisms of Hepatic Steatosis Prevention$127,683
K08 · FY2008 · DK · contact PI
Mechanisms of Hepatic Steatosis Prevention$127,683
K08 · FY2007 · DK · contact PI
Mechanisms of Hepatic Steatosis Prevention$128,763
K08 · FY2006 · DK · contact PI
Mechanisms of Hepatic Steatosis Prevention$127,683
K08 · FY2005 · DK